drugset / Trial / NCT07515820

SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study

NCT07515820

Phase 2 Not yet recruiting 12 enrolled Meng Qiu Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of SHR-3821 combined with fruquintinib in the advanced colorectal cancer after failure of standard therapy

Timeline

Start
2026-04-27
Primary completion
2027-07-28
Completion
2028-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule Oral
Subject SHR-3821 Unknown Intravenous

Indications